<p>Orchestra BioMed（纳斯达克股票代码：OBIO - 获取免费报告）在周二发布给客户和投资者的研究报告中，B. Riley Financial 的股票研究人员将其目标价格从 12.00 美元下调至 10.00 美元，Benzinga 报道。该公司目前对该股票给予 “买入” 评级。B. Riley Financial 的目标价格意味着该公司当前价格有 148.45% 的潜在上涨空间。</p>
<p>获取 <strong>Orchestra BioMed</strong> 的提醒：</p>
<p>其他一些研究公司也最近对 OBIO 发表了看法。HC Wainwright 在 5 月 14 日的报告中重申了 “买入” 评级，并将 Orchestra BioMed 的目标价格设定为 10.00 美元。Weiss Ratings 在 4 月 21 日的报告中将 Orchestra BioMed 的评级从 “卖出（d-）” 下调至 “卖出（e+）”。巴克莱在 5 月 13 日的报告中将 Orchestra BioMed 的目标价格从 12.00 美元上调至 13.00 美元，并给予该公司 “超配” 评级。Chardan Capital 在 3 月 12 日的报告中重申了 “买入” 评级，并将 Orchestra BioMed 的目标价格设定为 20.00 美元。最后，华尔街 Zen 在周六的报告中将 Orchestra BioMed 的评级从 “持有” 下调至 “卖出”。五位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，共识目标价格为 13.60 美元。</p>
<p><strong>获取我们最新的 Orchestra BioMed 股票报告</strong></p>
<h2>Orchestra BioMed 股票上涨 1.1%</h2>
<p>在周二的午盘交易中，OBIO 的股票上涨了 0.05 美元，达到 4.03 美元。该公司的股票交易量为 462,734 股，而其平均交易量为 215,212 股。该公司的 50 日移动平均线为 4.28 美元，200 日移动平均线为 4.27 美元。公司的市值为 2.4102 亿美元，市盈率为-4.15，贝塔值为 0.52。Orchestra BioMed 的 1 年最低价为 2.20 美元，1 年最高价为 5.42 美元。该公司的速动比率为 7.01，流动比率为 7.03，债务与股本比率为 0.35。</p>
<p>Orchestra BioMed（纳斯达克股票代码：OBIO - 获取免费报告）在 5 月 12 日最后发布了其财报。该公司报告每股收益（EPS）为-0.33 美元，超出分析师的共识预期（-0.40 美元）0.07 美元。Orchestra BioMed 的股本回报率为-157.46%，净利润率为-166.96%。该公司在本季度的收入为 11 万美元，而分析师预期为 92 万美元。作为一个整体，分析师预测 Orchestra BioMed 在当前财政年度将发布-1.62 的每股收益。</p>
<h2>Orchestra BioMed 的内部买卖</h2>
<p>在其他 Orchestra BioMed 的新闻中，董事 Jason Aryeh 在 5 月 15 日的交易中购买了 8,971 股该公司的股票。该股票的平均购买价格为每股 3.90 美元，总交易额为 34,986.90 美元。交易后，该董事持有 117,453 股该公司的股票，价值约为 458,066.70 美元。此次交易使其持股增加了 8.27%。该购买在向证券交易委员会提交的文件中披露，文件可在此链接查看。此外，内部人士 David P. Hochman 在 3 月 13 日的交易中购买了 10,000 股该公司的股票。该股票的平均购买价格为每股 4.29 美元，总价值为 42,900.00 美元。交易后，该内部人士直接持有 1,086,467 股该公司的股票，价值约为 4,660,943.43 美元。此次交易使其持股增加了 0.93%。该购买的 SEC 文件提供了更多信息。在过去 90 天内，内部人士购买了价值 179,337 美元的 43,971 股公司股票。内部人士持有该公司 7.50% 的股份。</p>
<h2>Orchestra BioMed 的机构交易</h2>
<p>机构投资者和对冲基金最近对该公司的持仓进行了调整。Virtu Financial LLC 在第四季度购买了 Orchestra BioMed 的新股份，价值 57,000 美元。Jane Street Group LLC 在第二季度购买了 Orchestra BioMed 的新股份，价值 50,000 美元。XTX Topco Ltd 在第二季度购买了 Orchestra BioMed 的新股份，价值 45,000 美元。Creative Planning 在第二季度购买了 Orchestra BioMed 的新股份，价值 40,000 美元。最后，Bank of America Corp DE 在第一季度将其在 Orchestra BioMed 的持仓增加了 200.7%。Bank of America Corp DE 现在拥有 52,761 股该公司的股票，价值 224,000 美元，此前在上个季度又购买了 35,214 股。机构投资者持有该公司 53.20% 的股份。</p>
<h2>影响 Orchestra BioMed 的主要头条新闻</h2>
<p>以下是本周影响 Orchestra BioMed 的主要新闻：</p>
<ul>
<li>积极情绪：董事 Eric Fain 以每股 4.13 美元购买了 20,000 股，显示出管理层的信心，并增加了看涨的内部购买趋势。SEC 文件</li>
<li>积极情绪：内部人士 David P. Hochman 也以每股 3.77 美元购买了 5,000 股，进一步表明公司内部人士的信心。SEC 文件</li>
<li>积极情绪：HC Wainwright 重申了 “买入” 评级和 “10 美元目标价格”，同时略微上调了 2026 年和 2027 年的短期每股收益预期，这可能会让投资者放心，华尔街仍然看到有意义的上涨空间。分析师覆盖</li>
<li>积极情绪：该公司表示管理层将参加 Jefferies 全球医疗保健会议，如果投资者期待有关管道进展或合作的更新，这可能会成为催化剂。会议公告</li>
<li>中性情绪：Orchestra BioMed 最新的财报显示每股损失小于预期，但收入仍远低于预期，因此整体报告是混合的。财报</li>
</ul>
<h2>关于 Orchestra BioMed</h2>
<p>（获取免费报告）</p>
<p>Orchestra BioMed, Inc NASDAQ: OBIO 是一家临床阶段的生物制药公司，致力于开发针对炎症、纤维化和肿瘤疾病的靶向疗法。该公司的研究重点是新型小分子项目，旨在通过利用专有的前药和靶向抑制剂平台来解决高未满足需求的疾病。Orchestra BioMed 的产品线包括主要候选药物 OBI-3424，这是一种由 AKR1C3 激活的前药，用于治疗特定的实体肿瘤，以及旨在抑制病理性炎症和纤维化的下一代调节剂。</p>
<p>Orchestra BioMed 在北美进行早期和中期临床研究，与关键意见领袖和学术中心紧密合作，以推进其项目。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票比 Orchestra BioMed 更好</li>
<li>HIVE 利用电力进行 AI 转型</li>
<li>深入分析 NVIDIA 最新的投资组合动向</li>
<li>Brady Corp 构建了一个巨大的 AI 驱动的突破</li>
<li>为什么 Home Depot 的抛售可能成为一个巨大的机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资$1,000 在 Orchestra BioMed 吗？</h2>
<p>在考虑投资 Orchestra BioMed 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Orchestra BioMed 并不在名单上。</p>
<p>虽然 Orchestra BioMed 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

OBIO

医药突破 ETF - ALPS

动态生物技术与基因组 ETF - Invesco

纽交所高增长板生物技术指数 ETF - First Trust

生物科技 ETF - VanEck Vectors

标普生物技术 3 倍做多 - Direxion

标普生物技术 ETF - SPDR

2 倍做多纳斯达克生物技术 ETF - ProShares

纳斯达克生物科技指数 ETF - iShares Nasdaq

<p>B. Riley Financial 将 Orchestra BioMed (NASDAQ:OBIO) 的目标股价从 12.00 美元下调至 10.00 美元，同时维持 “买入” 评级。这个新目标暗示从当前价格来看，潜在上涨幅度为 148.45%。其他分析师的观点各异，有的重申 “买入” 评级，有的则下调了该股票的评级。目前，OBIO 的股价为 4.03 美元，市值为 2.4102 亿美元</p>

<p>Orchestra BioMed (NASDAQ:OBIO - Get Free Report) had its price objective decreased by equities researchers at B. Riley Financial from $12.00 to $10.00 in a research report issued to clients and investors on Tuesday,Benzinga reports. The firm currently has a &#34;buy&#34; rating on the stock. B. Riley Financial's price objective would indicate a potential upside of 148.45% from the company's current price.</p>
<div class="lb-trans"><p>Orchestra BioMed（纳斯达克股票代码：OBIO - 获取免费报告）在周二发布给客户和投资者的研究报告中，B. Riley Financial 的股票研究人员将其目标价格从 12.00 美元下调至 10.00 美元，Benzinga 报道。该公司目前对该股票给予 “买入” 评级。B. Riley Financial 的目标价格意味着该公司当前价格有 148.45% 的潜在上涨空间。</p>
</div><p>Get <strong>Orchestra BioMed</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Orchestra BioMed</strong> 的提醒：</p>
</div><p>A number of other research firms also recently weighed in on OBIO. HC Wainwright reaffirmed a &#34;buy&#34; rating and set a $10.00 price objective on shares of Orchestra BioMed in a report on Thursday, May 14th. Weiss Ratings downgraded Orchestra BioMed from a &#34;sell (d-)&#34; rating to a &#34;sell (e+)&#34; rating in a report on Tuesday, April 21st. Barclays lifted their price objective on Orchestra BioMed from $12.00 to $13.00 and gave the company an &#34;overweight&#34; rating in a report on Wednesday, May 13th. Chardan Capital reaffirmed a &#34;buy&#34; rating and set a $20.00 price objective on shares of Orchestra BioMed in a report on Thursday, March 12th. Finally, Wall Street Zen downgraded Orchestra BioMed from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a report on Saturday. Five equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has an average rating of &#34;Moderate Buy&#34; and a consensus target price of $13.60.</p>
<div class="lb-trans"><p>其他一些研究公司也最近对 OBIO 发表了看法。HC Wainwright 在 5 月 14 日的报告中重申了 “买入” 评级，并将 Orchestra BioMed 的目标价格设定为 10.00 美元。Weiss Ratings 在 4 月 21 日的报告中将 Orchestra BioMed 的评级从 “卖出（d-）” 下调至 “卖出（e+）”。巴克莱在 5 月 13 日的报告中将 Orchestra BioMed 的目标价格从 12.00 美元上调至 13.00 美元，并给予该公司 “超配” 评级。Chardan Capital 在 3 月 12 日的报告中重申了 “买入” 评级，并将 Orchestra BioMed 的目标价格设定为 20.00 美元。最后，华尔街 Zen 在周六的报告中将 Orchestra BioMed 的评级从 “持有” 下调至 “卖出”。五位股票研究分析师对该股票给予了买入评级，一位给予了持有评级，一位给予了卖出评级。根据 MarketBeat 的数据，该股票的平均评级为 “适度买入”，共识目标价格为 13.60 美元。</p>
</div><p><strong>Get Our Latest Stock Report on Orchestra BioMed</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 Orchestra BioMed 股票报告</strong></p>
</div><h2>Orchestra BioMed Stock Up 1.1%</h2>
<div class="lb-trans"><h2>Orchestra BioMed 股票上涨 1.1%</h2>
</div><p>Shares of OBIO traded up $0.05 during mid-day trading on Tuesday, reaching $4.03. The company's stock had a trading volume of 462,734 shares, compared to its average volume of 215,212. The business has a fifty day moving average of $4.28 and a 200 day moving average of $4.27. The company has a market cap of $241.02 million, a price-to-earnings ratio of -4.15 and a beta of 0.52. Orchestra BioMed has a 1 year low of $2.20 and a 1 year high of $5.42. The company has a quick ratio of 7.01, a current ratio of 7.03 and a debt-to-equity ratio of 0.35.</p>
<div class="lb-trans"><p>在周二的午盘交易中，OBIO 的股票上涨了 0.05 美元，达到 4.03 美元。该公司的股票交易量为 462,734 股，而其平均交易量为 215,212 股。该公司的 50 日移动平均线为 4.28 美元，200 日移动平均线为 4.27 美元。公司的市值为 2.4102 亿美元，市盈率为-4.15，贝塔值为 0.52。Orchestra BioMed 的 1 年最低价为 2.20 美元，1 年最高价为 5.42 美元。该公司的速动比率为 7.01，流动比率为 7.03，债务与股本比率为 0.35。</p>
</div><p>Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last released its earnings results on Tuesday, May 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.40) by $0.07. Orchestra BioMed had a negative return on equity of 157.46% and a negative net margin of 166.96%.The company had revenue of $0.11 million during the quarter, compared to analyst estimates of $0.92 million. As a group, analysts forecast that Orchestra BioMed will post -1.62 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Orchestra BioMed（纳斯达克股票代码：OBIO - 获取免费报告）在 5 月 12 日最后发布了其财报。该公司报告每股收益（EPS）为-0.33 美元，超出分析师的共识预期（-0.40 美元）0.07 美元。Orchestra BioMed 的股本回报率为-157.46%，净利润率为-166.96%。该公司在本季度的收入为 11 万美元，而分析师预期为 92 万美元。作为一个整体，分析师预测 Orchestra BioMed 在当前财政年度将发布-1.62 的每股收益。</p>
</div><h2>Insider Buying and Selling at Orchestra BioMed</h2>
<div class="lb-trans"><h2>Orchestra BioMed 的内部买卖</h2>
</div><p>In other Orchestra BioMed news, Director Jason Aryeh bought 8,971 shares of the company's stock in a transaction on Friday, May 15th. The stock was bought at an average price of $3.90 per share, for a total transaction of $34,986.90. Following the transaction, the director owned 117,453 shares of the company's stock, valued at approximately $458,066.70. The trade was a 8.27% increase in their position. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which is available at this link. Also, insider David P. Hochman bought 10,000 shares of the company's stock in a transaction on Friday, March 13th. The shares were acquired at an average price of $4.29 per share, with a total value of $42,900.00. Following the transaction, the insider directly owned 1,086,467 shares in the company, valued at approximately $4,660,943.43. The trade was a 0.93% increase in their position. The SEC filing for this purchase provides additional information. In the last 90 days, insiders acquired 43,971 shares of company stock worth $179,337. Insiders own 7.50% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Orchestra BioMed 的新闻中，董事 Jason Aryeh 在 5 月 15 日的交易中购买了 8,971 股该公司的股票。该股票的平均购买价格为每股 3.90 美元，总交易额为 34,986.90 美元。交易后，该董事持有 117,453 股该公司的股票，价值约为 458,066.70 美元。此次交易使其持股增加了 8.27%。该购买在向证券交易委员会提交的文件中披露，文件可在此链接查看。此外，内部人士 David P. Hochman 在 3 月 13 日的交易中购买了 10,000 股该公司的股票。该股票的平均购买价格为每股 4.29 美元，总价值为 42,900.00 美元。交易后，该内部人士直接持有 1,086,467 股该公司的股票，价值约为 4,660,943.43 美元。此次交易使其持股增加了 0.93%。该购买的 SEC 文件提供了更多信息。在过去 90 天内，内部人士购买了价值 179,337 美元的 43,971 股公司股票。内部人士持有该公司 7.50% 的股份。</p>
</div><h2>Institutional Trading of Orchestra BioMed</h2>
<div class="lb-trans"><h2>Orchestra BioMed 的机构交易</h2>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the business. Virtu Financial LLC bought a new stake in shares of Orchestra BioMed in the 4th quarter valued at $57,000. Jane Street Group LLC bought a new stake in shares of Orchestra BioMed in the 2nd quarter valued at $50,000. XTX Topco Ltd bought a new stake in shares of Orchestra BioMed in the 2nd quarter valued at $45,000. Creative Planning bought a new stake in shares of Orchestra BioMed in the 2nd quarter valued at $40,000. Finally, Bank of America Corp DE increased its position in shares of Orchestra BioMed by 200.7% in the 1st quarter. Bank of America Corp DE now owns 52,761 shares of the company's stock valued at $224,000 after buying an additional 35,214 shares in the last quarter. Institutional investors own 53.20% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近对该公司的持仓进行了调整。Virtu Financial LLC 在第四季度购买了 Orchestra BioMed 的新股份，价值 57,000 美元。Jane Street Group LLC 在第二季度购买了 Orchestra BioMed 的新股份，价值 50,000 美元。XTX Topco Ltd 在第二季度购买了 Orchestra BioMed 的新股份，价值 45,000 美元。Creative Planning 在第二季度购买了 Orchestra BioMed 的新股份，价值 40,000 美元。最后，Bank of America Corp DE 在第一季度将其在 Orchestra BioMed 的持仓增加了 200.7%。Bank of America Corp DE 现在拥有 52,761 股该公司的股票，价值 224,000 美元，此前在上个季度又购买了 35,214 股。机构投资者持有该公司 53.20% 的股份。</p>
</div><h2>Key Headlines Impacting Orchestra BioMed</h2>
<div class="lb-trans"><h2>影响 Orchestra BioMed 的主要头条新闻</h2>
</div><p>Here are the key news stories impacting Orchestra BioMed this week:</p>
<div class="lb-trans"><p>以下是本周影响 Orchestra BioMed 的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Director Eric Fain bought 20,000 shares at $4.13 per share, signaling confidence from management and adding to the bullish insider-buying trend. SEC filing</li>
<li>Positive Sentiment: Insider David P. Hochman also purchased 5,000 shares at $3.77, adding another vote of confidence from a company insider. SEC filing</li>
<li>Positive Sentiment: HC Wainwright reiterated a <strong>Buy</strong> rating and <strong>$10 price target</strong>, while slightly raising near-term EPS estimates for 2026 and 2027, which may reassure investors that Wall Street still sees meaningful upside. Analyst coverage</li>
<li>Positive Sentiment: The company said management will participate in the Jefferies Global Healthcare Conference, which could provide a catalyst if investors look for updates on pipeline progress or partnerships. Conference announcement</li>
<li>Neutral Sentiment: Orchestra BioMed’s latest earnings showed a smaller-than-expected loss per share, but revenue remained well below estimates, so the report was mixed overall. Earnings report</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：董事 Eric Fain 以每股 4.13 美元购买了 20,000 股，显示出管理层的信心，并增加了看涨的内部购买趋势。SEC 文件</li>
<li>积极情绪：内部人士 David P. Hochman 也以每股 3.77 美元购买了 5,000 股，进一步表明公司内部人士的信心。SEC 文件</li>
<li>积极情绪：HC Wainwright 重申了 “买入” 评级和 “10 美元目标价格”，同时略微上调了 2026 年和 2027 年的短期每股收益预期，这可能会让投资者放心，华尔街仍然看到有意义的上涨空间。分析师覆盖</li>
<li>积极情绪：该公司表示管理层将参加 Jefferies 全球医疗保健会议，如果投资者期待有关管道进展或合作的更新，这可能会成为催化剂。会议公告</li>
<li>中性情绪：Orchestra BioMed 最新的财报显示每股损失小于预期，但收入仍远低于预期，因此整体报告是混合的。财报</li>
</ul>
</div><h2>About Orchestra BioMed</h2>
<div class="lb-trans"><h2>关于 Orchestra BioMed</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Orchestra BioMed, Inc NASDAQ: OBIO is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company's research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed's pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.</p>
<div class="lb-trans"><p>Orchestra BioMed, Inc NASDAQ: OBIO 是一家临床阶段的生物制药公司，致力于开发针对炎症、纤维化和肿瘤疾病的靶向疗法。该公司的研究重点是新型小分子项目，旨在通过利用专有的前药和靶向抑制剂平台来解决高未满足需求的疾病。Orchestra BioMed 的产品线包括主要候选药物 OBI-3424，这是一种由 AKR1C3 激活的前药，用于治疗特定的实体肿瘤，以及旨在抑制病理性炎症和纤维化的下一代调节剂。</p>
</div><p>Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.</p>
<div class="lb-trans"><p>Orchestra BioMed 在北美进行早期和中期临床研究，与关键意见领袖和学术中心紧密合作，以推进其项目。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Orchestra BioMed</li>
<li>HIVE Weaponizes Power for an AI Pivot</li>
<li>A Deep Dive Into NVIDIA’s Latest Portfolio Moves</li>
<li>Brady Corp Wires Up a Massive AI-Powered Breakout</li>
<li>Why Home Depot’s Sell-Off Could Become a Huge Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Orchestra BioMed 更好</li>
<li>HIVE 利用电力进行 AI 转型</li>
<li>深入分析 NVIDIA 最新的投资组合动向</li>
<li>Brady Corp 构建了一个巨大的 AI 驱动的突破</li>
<li>为什么 Home Depot 的抛售可能成为一个巨大的机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=OBIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送邮件至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Orchestra BioMed Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资$1,000 在 Orchestra BioMed 吗？</h2>
</div><p>Before you consider Orchestra BioMed, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资 Orchestra BioMed 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orchestra BioMed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Orchestra BioMed 并不在名单上。</p>
</div><p>While Orchestra BioMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Orchestra BioMed 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Orchestra BioMed (NASDAQ:OBIO) Given New $10.00 Price Target at B. Riley Financial

Market Beat

Orchestra BioMed

巴克莱银行

Virtu Finc

美国银行

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B. Riley Financial-存托优先股A

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

Orchestra BioMed（NASDAQ:OBIO）被 B. Riley Financial 设定了新的目标价为 10.00 美元